Aziyo Biologics launches OsteGro for spinal fusion, other procedures: 4 insights

Written by Shayna Korol | March 22, 2018 | Print  |

Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.

Here are four things to know.

1. OsteGro is developed with Aziyo's proprietary processing methods, resulting in a bone graft that acts as a scaffold for new bone growth. The matrix is regulated as a human tissue allograft.

2. Composed of cancellous bone and partially demineralized cortical bone, OsteGro is designed to be easily molded to produce the desired shape. It is sterile and can be stored at room temperature.

3. OsteGro is the third product in Aziyo's portfolio, which includes ViBone, a viable bone matrix, and OsteSpine, a complete line of precision machined cervical spacers.

4. The biologics segment of the U.S. orthopedic market is estimated to total approximately $2 billion in sales annually.

More articles on biologics:

Dr. Greg Merrell treats first US patient with Cartiva Synthetic Cartilage Implant for basal joint arthritis: 5 things to know

5 key vendors in the global stem cell therapy market

KICVentures acquires Amend Surgical to enhance biologics portfolio: 5 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months